Literature DB >> 7579398

Idiotype-reactive T-cell subsets and tumor load in monoclonal gammopathies.

Q Yi1, A Osterborg, S Bergenbrant, H Mellstedt, G Holm, A K Lefvert.   

Abstract

The presence of idiotype-reactive T-cell subsets and their relation to the tumor load were analyzed in 9 patients with monoclonal gammopathy of undetermined significance (MGUS), in 12 patients with multiple myeloma (MM) clinical stage I, and in 9 patients with MM stage II/III. An enzyme-linked immunospot assay was used to identify interferon-gamma (IFN-gamma)-, interleukin-2 (IL-2)-, or IL-4-secreting T cells after stimulation by F(ab')2 fragments of monoclonal IgG. The response to autologous IgG was significantly higher than that induced by isotypic monoclonal IgG. Comparable results were obtained in a proliferation assay (3H-thymidine incorporation). A total of 8 of 9 patients with MGUS, 7 of 12 patients with MM stage I, and 3 of 9 with MM stage II/III had T cells secreting IFN-gamma and/or IL-2 (T helper [Th1] type-1 cells), whereas cells secreting both Th1 and Th2 or Th0 types of cytokines were more frequent in patients with MM, particularly in those with MM stage II/III. The number and frequency of Th1-type cells were significantly higher in MGUS patients as compared with those of MM stage II/III. The results indicate that idiotype-reactive T cells of the Th1 and Th2 or Th0 subsets were present in MGs and might provide indirect evidence that idiotype-reactive Th1-type cells may have a regulatory impact on the human tumor B cells.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7579398

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  22 in total

1.  Deregulated cytokine network and defective Th1 immune response in multiple myeloma.

Authors:  M A Frassanito; A Cusmai; F Dammacco
Journal:  Clin Exp Immunol       Date:  2001-08       Impact factor: 4.330

2.  Vaccination with dendritic cell/tumor fusion cells results in cellular and humoral antitumor immune responses in patients with multiple myeloma.

Authors:  Jacalyn Rosenblatt; Baldev Vasir; Lynne Uhl; Simona Blotta; Claire Macnamara; Poorvi Somaiya; Zekui Wu; Robin Joyce; James D Levine; Dilani Dombagoda; Yan Emily Yuan; Karen Francoeur; Donna Fitzgerald; Paul Richardson; Edie Weller; Kenneth Anderson; Donald Kufe; Nikhil Munshi; David Avigan
Journal:  Blood       Date:  2010-10-28       Impact factor: 22.113

3.  Treatment of multiple myeloma with adoptively transferred chimeric NKG2D receptor-expressing T cells.

Authors:  A Barber; K R Meehan; C L Sentman
Journal:  Gene Ther       Date:  2011-01-06       Impact factor: 5.250

Review 4.  Peptide vaccines for hematological malignancies: a missed promise?

Authors:  Monica Bocchia; Marzia Defina; Lara Aprile; Anna Sicuranza
Journal:  Int J Hematol       Date:  2014-01-08       Impact factor: 2.490

5.  Optimizing dendritic cell-based immunotherapy in multiple myeloma: intranodal injections of idiotype-pulsed CD40 ligand-matured vaccines led to induction of type-1 and cytotoxic T-cell immune responses in patients.

Authors:  Qing Yi; Susann Szmania; John Freeman; Jianfei Qian; Nancy A Rosen; Sanjaya Viswamitra; Michele Cottler-Fox; Bart Barlogie; Guido Tricot; Frits van Rhee
Journal:  Br J Haematol       Date:  2010-07-07       Impact factor: 6.998

Review 6.  Immune therapies.

Authors:  Rao H Prabhala; Nikhil C Munshi
Journal:  Hematol Oncol Clin North Am       Date:  2007-12       Impact factor: 3.722

Review 7.  Novel immunotherapies.

Authors:  Qing Yi
Journal:  Cancer J       Date:  2009 Nov-Dec       Impact factor: 3.360

Review 8.  Immunotherapy for Multiple Myeloma, Past, Present, and Future: Monoclonal Antibodies, Vaccines, and Cellular Therapies.

Authors:  Rebecca Karp Leaf; Hearn Jay Cho; David Avigan
Journal:  Curr Hematol Malig Rep       Date:  2015-12       Impact factor: 3.952

Review 9.  Oligoclonal T cells in human cancer.

Authors:  E Halapi
Journal:  Med Oncol       Date:  1998-12       Impact factor: 3.064

10.  Cyclin D1 as a universally expressed mantle cell lymphoma-associated tumor antigen for immunotherapy.

Authors:  M Wang; L Sun; J Qian; X Han; L Zhang; P Lin; Z Cai; Q Yi
Journal:  Leukemia       Date:  2009-02-19       Impact factor: 11.528

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.